CMR Surgical raises more than $200m to accelerate growth in US and globally
Global surgical robotics company CMR Surgical in Cambridge has closed a funding round of more than $200 million to underpin worldwide expansion – notably in the US.
The haul has been raised through a combination of equity and debt capital to support the company’s ambitious growth plans.
Cambridge Innovation Capital co-leads $31M seed financing for TRIMTECH Therapeutics to advance neurodegenerative disease treatments
Cambridge Innovation Capital (CIC), a leading investor in life sciences and deep tech companies, today announces its role as a co-lead investor in TRIMTECH Therapeutics’ $31 million (£25 million) seed funding round.
British Patient Capital announces £20m commitment to Cambridge Innovation Capital £100m Opportunity Fund
British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £20 million cornerstone commitment to Cambridge Innovation Capital’s (CIC) £100 million Opportunity Fund, alongside Aviva Investors.
New £100m Cambridge Innovation Capital fund launched
Cambridge Innovation Capital has launched a new £100 million Opportunity Fund – anchored by Aviva Investors and British Patient Capital – to invest in growing DeepTech and life science companies.
Epitopea announces license and research collaboration agreement with MSD to identify cryptigenTM tumor-specific antigens
Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename of Merck & Co.
Cambridge GaN Devices secures $32M to drive growth in power semiconductor industry
Cambridge GaN Devices (CGD), a leading innovator in gallium nitride (GaN) power devices, has successfully closed a $32 million Series C funding round.
Salience Labs closed Series A round led by Applied Ventures and ICM HPQC Fund
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and App
An open letter to the Government underscoring the critical role Greater Cambridge can play in the UK’s sustainable and inclusive national renewal
If science were a country then Cambridge would likely be its capital, and if discovery were a global competition the city and region would regularly be winning for Britain. That’s because Greater Cambridge is where innovation makes history and where the future comes first.
Cambridge Innovation Capital (CIC) invests in Forefront RF
Cambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge UK ecosystem, is pleased to announce its investment in Forefront RF, with the completion of a £16 million Series A financing round.
Oxford-Cambridge region should be science ‘jewel’
Industry leaders have urged the government to make the Oxford-Cambridge region the “crown jewel” of European science and innovation.
CIC wins Best Performing Investor of the Year award by One Nucleus
For the first time, life science innovators, companies and their supporters were invited to celebrate their success in various categories, at the inaugural One Nucleus Annual Awards.
Winners
Pragmatic Semiconductor secures £182m ($231m) investment led by M&G and UK Infrastructure Bank
Largest ever European semiconductor venture funding round supports further expansion of manufacturing in the UK.
Cambridge Innovation Capital announces its investment in T-Therapeutics’ £48 Million Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in T-Therapeutics’ £48 Million Series A funding round alongside leading European and US life science investors Sofinnova Partners, F-Prime Capital and Digitalis Ventures, with participation from Sanofi Ventures and the University of Cambridge…
AI start-up founders reveal artificial intelligence trends for 2023
With artificial intelligence (AI) innovation surging across business, we gauge the views of AI start-up founders on the biggest trends in the space this year.
Cambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in Complement Therapeutics’ €72 Million Series A funding round led
Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in Mosaic Therapeutics $28m Series A funding round.
Cambridge Innovation Capital raises £225 million ($300 million) for Fund II
Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, raises £225 million ($300 million) for its oversubscribed second fund (Fund II).
CIC participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics
Cambridge Innovation Capital participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics.Largest microbiome-related financing in Europe will advance Phase 1B clinical trials in immuno-oncology and ulcerative colitis.
Cambridge Innovation Capital looks back on 'transformational year'
Cambridge Innovation Capital presents a video which summarises some of its achievements in 2021, which was a "transformational year" for CIC, according to Managing Partner Andrew Williamson.
CIC participates in Pretzel Therapeutics’ financing round to develop first-in-class treatments for mitochondrial disease
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Cambridge ecosystem, is pleased to announce its participation in the financing raised by Pretzel Therapeutics, to support development of novel therapeutics designed to address currently untreatable conditions.
Origami raises £20 million in Series C funding round led by Barclays
Cambridge based Origami has raised £20.5m of new funding to help drive its next phase of growth.
New Cambridge accelerator for deeptech startups launches with five machine learning investments
Deeptech Labs (DTL), a new post-seed accelerator aimed at deep technology (deeptech) start-ups, has been founded in Cambridge to bring the benefits of its innovation ecosystem to post-Seed deeptech companies from the UK and Europe.
Sense raises $50m Series B to accelerate launch of COVID-19 molecular test
Sense Biodetection (Sense), has announced that it has raised a $50m Series B investment to advance commercialisation of its Veros™ COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enable improved access, outcomes, and value through patient-focused decentralised healthcare.
CIC participates in Gyroscope Therapeutics’ £107.8 million Series C financing
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Cambridge ecosystem, is pleased to announce its participation in the £107.8 million ($148 million) Series C financing raised by Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye.
How to collaborate with Alibaba: IP, legislation and boosting market penetration
A webinar next month is aimed at small-medium sized enterprises that intend to partner with the BATs (Baidu, Alibaba, and Tencent) or to operate a technology company that services the Chinese market.